As per Intent Market Research, the Monobody-Based Therapeutic Drugs Market was valued at USD 1.9 Billion in 2024-e and will surpass USD 4.3 Billion by 2030; growing at a CAGR of 12.6% during 2025-2030.
The Monobody-Based Therapeutic Drugs market has seen substantial growth driven by advancements in biotechnology and a growing focus on precision medicine. These therapeutics provide targeted solutions for complex diseases, offering enhanced efficacy and reduced side effects compared to traditional treatments. With continuous innovation and increasing investment in research and development, the market is poised for further expansion.
Oncology Segment is Largest Owing to Rising Cancer Prevalence
The Oncology segment remains the largest within the Monobody-Based Therapeutic Drugs market. This dominance is driven by the increasing incidence of cancer globally and the demand for targeted therapies with fewer side effects. Monobody-based therapeutics in oncology offer high specificity for cancer cells, reducing damage to healthy tissues and improving patient outcomes. The continuous advancement in technology for cancer treatment, along with extensive R&D efforts, has established oncology as a significant driver of market growth.
Drug Class Segment: Monobody-Based Fusion Proteins Fastest Growing
Monobody-Based Fusion Proteins are emerging as the fastest-growing drug class in the Monobody-Based Therapeutic Drugs market. These therapeutics combine the properties of monobody antibodies with additional functionalities, enhancing their therapeutic capabilities. With applications in oncology and autoimmune disorders, the versatility and efficacy of fusion proteins make them highly sought after. As companies continue to explore and optimize these innovative therapies, their adoption is expected to accelerate rapidly.
Therapeutic Application: Precision Medicine for Rare Diseases
Precision Medicine, a therapeutic application within the Monobody-Based Therapeutic Drugs market, is experiencing remarkable growth. Precision Medicine focuses on tailoring treatments to individual patient profiles, making it ideal for rare and complex diseases. Monobody therapeutics offer unique advantages in this area, providing highly specific targeting and minimizing off-target effects. With the rise in personalized medicine, this segment is expected to expand significantly, driving innovation in rare disease management.
Largest Region: North America Leading Innovation and Adoption
North America holds the largest share in the Monobody-Based Therapeutic Drugs market, primarily due to its advanced healthcare infrastructure, robust R&D capabilities, and high adoption of innovative therapies. Countries like the U.S. and Canada are home to leading biotech companies and research institutions that continue to spearhead the development of Monobody-based therapeutics. The region's emphasis on precision medicine and personalized care has established it as a global leader in this space.
Competitive Landscape and Leading Companies
The Monobody-Based Therapeutic Drugs market is highly competitive, with several established and emerging players vying for dominance. Leading companies such as Genmab A/S, Xencor, and Regeneron Pharmaceuticals are at the forefront, driving innovation through strategic partnerships, acquisitions, and advanced clinical trials. The market’s competitive nature is fueled by continuous advancements in drug development, ensuring a dynamic environment with ongoing research and collaboration across global regions.
Recent Developments:
- Genmab A/S announced the successful clinical trial results of its Monobody-Based therapeutic for oncology indications.
- Xencor launched a novel Monobody-Based drug targeting autoimmune disorders, receiving significant funding from venture capitalists.
- UCB Pharma acquired a biotech firm specializing in Monobody Therapeutics to expand its neurology drug pipeline.
- WuXi AppTec partnered with several global pharmaceutical companies to co-develop Monobody-based therapies for cancer treatment.
- Thermo Fisher Scientific introduced a new advanced Monobody fusion protein manufacturing platform to streamline production.
List of Leading Companies:
- AbCellera
- Adimab LLC
- Genmab A/S
- ImmunoGen
- MacroGenics
- Selexis SA
- Ligand Pharmaceuticals
- Xencor
- Zymeworks Inc.
- WuXi AppTec
- Regeneron Pharmaceuticals
- ProMIS Neurosciences
- Pyxis Oncology
- UCB Pharma
- Thermo Fisher Scientific
Report Scope:
Report Features |
Description |
Market Size (2024-e) |
USD 1.9 Billion |
Forecasted Value (2030) |
USD 4.3 Billion |
CAGR (2025 – 2030) |
12.6% |
Base Year for Estimation |
2024-e |
Historic Year |
2023 |
Forecast Period |
2025 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Monobody-Based Therapeutic Drugs Market By Therapeutic Area (Oncology, Autoimmune Disorders, Infectious Diseases, Cardiovascular, Neurological Disorders), By Drug Class (Monobody-Based Antibodies, Monobody-Based Fusion Proteins, Bispecific Monobody Therapeutics), and By Therapeutic Application (Cancer Treatment, Chronic Illness Management, Precision Medicine, Rare Diseases); Global Insights & Forecast (2023 – 2030) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
AbCellera, Adimab LLC, Genmab A/S, ImmunoGen, MacroGenics, Selexis SA, Ligand Pharmaceuticals, Xencor, Zymeworks Inc., WuXi AppTec, Regeneron Pharmaceuticals, ProMIS Neurosciences, Pyxis Oncology, UCB Pharma, Thermo Fisher Scientific
|
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Monobody-Based Therapeutic Drugs Market, by Therapeutic Areas (Market Size & Forecast: USD Million, 2023 – 2030) |
4.1. Oncology |
4.2. Autoimmune Disorders |
4.3. Infectious Diseases |
4.4. Cardiovascular |
4.5. Neurological Disorders |
5. Monobody-Based Therapeutic Drugs Market, by Drug Class (Market Size & Forecast: USD Million, 2023 – 2030) |
5.1. Monobody-Based Antibodies |
5.2. Monobody-Based Fusion Proteins |
5.3. Bispecific Monobody Therapeutics |
5.4. Others |
6. Monobody-Based Therapeutic Drugs Market, by Therapeutic Application (Market Size & Forecast: USD Million, 2023 – 2030) |
6.1. Cancer Treatment |
6.2. Chronic Illness Management |
6.3. Precision Medicine |
6.4. Rare Diseases |
7. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
7.1. Regional Overview |
7.2. North America |
7.2.1. Regional Trends & Growth Drivers |
7.2.2. Barriers & Challenges |
7.2.3. Opportunities |
7.2.4. Factor Impact Analysis |
7.2.5. Technology Trends |
7.2.6. North America Monobody-Based Therapeutic Drugs Market, by Therapeutic Areas |
7.2.7. North America Monobody-Based Therapeutic Drugs Market, by Drug Class |
7.2.8. North America Monobody-Based Therapeutic Drugs Market, by Therapeutic Application |
7.2.9. By Country |
7.2.9.1. US |
7.2.9.1.1. US Monobody-Based Therapeutic Drugs Market, by Therapeutic Areas |
7.2.9.1.2. US Monobody-Based Therapeutic Drugs Market, by Drug Class |
7.2.9.1.3. US Monobody-Based Therapeutic Drugs Market, by Therapeutic Application |
7.2.9.2. Canada |
7.2.9.3. Mexico |
*Similar segmentation will be provided for each region and country |
7.3. Europe |
7.4. Asia-Pacific |
7.5. Latin America |
7.6. Middle East & Africa |
8. Competitive Landscape |
8.1. Overview of the Key Players |
8.2. Competitive Ecosystem |
8.2.1. Level of Fragmentation |
8.2.2. Market Consolidation |
8.2.3. Product Innovation |
8.3. Company Share Analysis |
8.4. Company Benchmarking Matrix |
8.4.1. Strategic Overview |
8.4.2. Product Innovations |
8.5. Start-up Ecosystem |
8.6. Strategic Competitive Insights/ Customer Imperatives |
8.7. ESG Matrix/ Sustainability Matrix |
8.8. Manufacturing Network |
8.8.1. Locations |
8.8.2. Supply Chain and Logistics |
8.8.3. Product Flexibility/Customization |
8.8.4. Digital Transformation and Connectivity |
8.8.5. Environmental and Regulatory Compliance |
8.9. Technology Readiness Level Matrix |
8.10. Technology Maturity Curve |
8.11. Buying Criteria |
9. Company Profiles |
9.1. AbCellera |
9.1.1. Company Overview |
9.1.2. Company Financials |
9.1.3. Product/Service Portfolio |
9.1.4. Recent Developments |
9.1.5. IMR Analysis |
*Similar information will be provided for other companies |
9.2. Adimab LLC |
9.3. Genmab A/S |
9.4. ImmunoGen |
9.5. MacroGenics |
9.6. Selexis SA |
9.7. Ligand Pharmaceuticals |
9.8. Xencor |
9.9. Zymeworks Inc. |
9.10. WuXi AppTec |
9.11. Regeneron Pharmaceuticals |
9.12. ProMIS Neurosciences |
9.13. Pyxis Oncology |
9.14. UCB Pharma |
9.15. Thermo Fisher Scientific |
10. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Monobody-Based Therapeutic Drugs Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Monobody-Based Therapeutic Drugs Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Monobody-Based Therapeutic Drugs Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA